Tepotinib With Gefitinib in Participants With Locally Advanced or Metastatic NSCLC (INSIGHT)

NCT01982955 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

88

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG: Tepotinib
DRUG: Gefitinib
DRUG: Pemetrexed
DRUG: Cisplatin
DRUG: Carboplatin

Sponsor

Merck KGaA, Darmstadt, Germany